Understand Unmet Needs in the Migraine Market Based on Key Opinion Leader Comments.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c68792) has announced the addition of Pipeline Insight: Migraine - Innovation Essential as Weak Late-stage Pipeline Fails to Hold off the Impact of Triptan Patent Expiries to their offering. After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era. Scope of this title: - Analysis of patient potential, unmet needs and clinical trial design in migraine - Overview of drugs in preregistration pre·reg·is·tra·tion n. An early registration, as for returning college students, that takes place before general registration. , Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA , II and I; with analysis of key companies involved in the R&D pipeline - Detailed profiles of key compounds in development for use in migraine, with forecasts of drug revenues to 2015 - Discussion of GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) and Pozens strategies and insight from key industry opinion leaders Highlights of this title: - Due to Imitrexs commercial success, GSK is the current migraine market leader. Trexima, co-developed by GSK and Pozen represents GSK's product line extension for its migraine franchise, but approval delays and the impending im·pend intr.v. im·pend·ed, im·pend·ing, im·pends 1. To be about to occur: Her retirement is impending. 2. US sumatriptan sumatriptan /su·ma·trip·tan/ (soo?mah-trip´tan) a selective serotonin receptor agonist used as the succinate salt in the acute treatment of migraine and cluster headaches. su·ma·trip·tan n. patent expiry will limit its success. - The next big thing in the prophylactic market will be the label expansion of Allergans Botox and Ipsens Dysport. Seven major market Botox and Dysport combined sales for migraine are forecast to grow to over $170m in 2015. - The presence of glutamatergic receptor inhibitors, NOS inhibitors and CGRP CGRP Calcitonin Gene-Related Peptide CGRP Controlled Goods Registration Program CGRP Coolant Group (TARTAR) CGRP Common Hardware Reference Platform antagonists, amongst others in early stage clinical trials, indicate companies are developing innovative drugs for the post triptan future. With all identified to play a role in the biological mechanisms of migraine, there holds great potential in such novel drug targets. Reasons to order your copy: - Understand unmet needs in the migraine market based on key opinion leader comments - Benchmark key late-stage migraine compounds against current market leaders - Assess the combined US, Japan, five major EU sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential Report breakdown Chapter 1 - Executive Summary Chapter 2 - Patient Potential 23 Chapter 3 - R&D Approach Chapter 4 - Migraine Pipeline Analysis Chapter 5 - Triptan Late-Stage Drug Analysis & Forecasts 81 Chapter 6 - Nsaid Late-Stage Drug Analysis & Forecasts 116 Chapter 7 - Botulinum Toxin Botulinum toxin (botulin) A neurotoxin made by Clostridium botulinum; causes paralysis in high doses, but is used medically in small, localized doses to treat disorders associated with involuntary muscle contraction and spasms, in addition to strabismus. Type-A Late-Stage Drug Analysis & Forecasts 140 Chapter 8 - Other 5-Ht-1 Receptor Modulator Modulator Any device or circuit by means of which a desired signal is impressed upon a higher-frequency periodic wave known as a carrier. The process is called modulation. The modulator may vary the amplitude, frequency, or phase of the carrier. Late-Stage Drug Analysis 163 Chapter 9 - Glutamate Receptor Glutamate is a neurotransmitter in nerve cells which binds to all glutamate receptors located on neuron membranes, and is an example of a transmembrane receptor. Function Glutamate is the most prominent neurotransmitter in the body,[1] Antagonist Late-Stage Drug Analysis Chapter 10 - Hormone Treatment Late-Stage Drug Analysis Chapter 11 - Vanilloid Vr1 Modulator Late-Stage Drug Analysis Chapter 12 - Sodium Channel Sodium channels (also known as "voltage-gated sodium channels") are integral membrane proteins that conduct sodium ions (Na+) through a cell's plasma membrane. Many of the ionotropic receptors are also able to conduct sodium ions. Blockers Late-Stage Drug Analysis Chapter 13 - Other Late-Stage Drug Analysis Chapter 14 - Appendices For more information visit http://www.researchandmarkets.com/reports/c68792. Source: Datamonitor |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion